(ARDX) Ardelyx - Ratings and Ratios
Kidney Drug, Bowel Drug
ARDX EPS (Earnings per Share)
ARDX Revenue
Description: ARDX Ardelyx
Ardelyx Inc, a biotechnology company listed on NASDAQ under the ticker symbol ARDX, operates in the United States. The companys stock performance and financial health are critical indicators of its potential for growth and return on investment.
From a financial perspective, Ardelyx has a market capitalization of approximately $1.3 billion, indicating a significant presence in the biotechnology sector. However, the companys Price-to-Earnings (P/E) ratio is currently at 0.00, suggesting that it is either not profitable or that its earnings are not being reflected in its stock price. The forward P/E ratio is also 0.00, implying that the market does not expect significant earnings in the near future. The Return on Equity (RoE) stands at -36.57%, indicating that the company is currently not generating profits from shareholders equity.
Key Performance Indicators (KPIs) such as revenue growth, R&D expenses as a percentage of revenue, and cash burn rate will be crucial in assessing Ardelyxs financial health and operational efficiency. The companys ability to manage its cash reserves, currently not disclosed, and reduce its cash burn will be vital in sustaining operations and achieving profitability.
Economic drivers for Ardelyx include the demand for its products, particularly in the gastrointestinal and cardio-renal therapeutic areas, where the company is focusing its drug development efforts. The success of its pipeline, including drugs like tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in patients with chronic kidney disease on dialysis, will be critical. Market competition, regulatory approvals, and pricing pressures will also significantly impact the companys financial performance.
Investors should closely monitor Ardelyxs progress in terms of clinical trial results, FDA approvals, and commercialization of its products. The companys ability to secure partnerships, manage its financial resources effectively, and navigate the complex regulatory landscape will be key determinants of its stock performance.
ARDX Stock Overview
| Market Cap in USD | 1,600m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2014-06-19 |
ARDX Stock Ratings
| Growth Rating | 33.7% |
| Fundamental | 30.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -15.1% |
| Analyst Rating | 4.64 of 5 |
ARDX Dividends
Currently no dividends paidARDX Growth Ratios
| Growth Correlation 3m | 92.5% |
| Growth Correlation 12m | -34% |
| Growth Correlation 5y | 18.3% |
| CAGR 5y | 69.94% |
| CAGR/Max DD 3y | 1.05 |
| CAGR/Mean DD 3y | 2.42 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | 0.19 |
| Beta | 0.570 |
| Volatility | 69.46% |
| Current Volume | 2896.5k |
| Average Volume 20d | 3043.2k |
| Stop Loss | 5.9 (-4.7%) |
| Signal | -1.07 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-56.4m TTM) > 0 and > 6% of Revenue (6% = 23.2m TTM) |
| FCFTA -0.10 (>2.0%) and ΔFCFTA 16.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 69.88% (prev 95.52%; Δ -25.63pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.11 (>3.0%) and CFO -53.5m > Net Income -56.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (239.9m) change vs 12m ago 2.28% (target <= -2.0% for YES) |
| Gross Margin 85.41% (prev 85.86%; Δ -0.46pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 95.31% (prev 61.14%; Δ 34.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.75 (EBITDA TTM -32.1m / Interest Expense TTM 24.0m) >= 6 (WARN >= 3) |
Altman Z'' -6.54
| (A) 0.58 = (Total Current Assets 351.6m - Total Current Liabilities 81.7m) / Total Assets 466.8m |
| (B) -2.03 = Retained Earnings (Balance) -945.6m / Total Assets 466.8m |
| warn (B) unusual magnitude: -2.03 — check mapping/units |
| (C) -0.10 = EBIT TTM -41.9m / Avg Total Assets 405.1m |
| (D) -2.89 = Book Value of Equity -945.6m / Total Liabilities 327.2m |
| Total Rating: -6.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 30.59
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -2.93% = -1.46 |
| 3. FCF Margin -11.87% = -4.45 |
| 4. Debt/Equity 1.45 = 1.53 |
| 5. Debt/Ebitda -6.31 = -2.50 |
| 6. ROIC - WACC (= -21.23)% = -12.50 |
| 7. RoE -36.57% = -2.50 |
| 8. Rev. Trend 82.62% = 6.20 |
| 9. EPS Trend -4.48% = -0.22 |
What is the price of ARDX shares?
Over the past week, the price has changed by -6.78%, over one month by +6.54%, over three months by +74.37% and over the past year by +0.65%.
Is Ardelyx a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARDX is around 6.17 USD . This means that ARDX is currently overvalued and has a potential downside of -0.32%.
Is ARDX a buy, sell or hold?
- Strong Buy: 8
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ARDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.4 | 83.5% |
| Analysts Target Price | 11.4 | 83.5% |
| ValueRay Target Price | 6.8 | 10.2% |
Last update: 2025-09-12 04:31
ARDX Fundamental Data Overview
CCE Cash And Equivalents = 238.5m USD (Cash And Short Term Investments, last quarter)
P/S = 4.1438
P/B = 11.4679
P/EG = -0.08
Beta = 0.732
Revenue TTM = 386.1m USD
EBIT TTM = -41.9m USD
EBITDA TTM = -32.1m USD
Long Term Debt = 201.4m USD (from longTermDebt, last quarter)
Short Term Debt = 1.18m USD (from shortTermDebt, last quarter)
Debt = 202.6m USD (Calculated: Short Term 1.18m + Long Term 201.4m)
Net Debt = 116.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.56b USD (1.60b + Debt 202.6m - CCE 238.5m)
Interest Coverage Ratio = -1.75 (Ebit TTM -41.9m / Interest Expense TTM 24.0m)
FCF Yield = -2.93% (FCF TTM -45.8m / Enterprise Value 1.56b)
FCF Margin = -11.87% (FCF TTM -45.8m / Revenue TTM 386.1m)
Net Margin = -14.60% (Net Income TTM -56.4m / Revenue TTM 386.1m)
Gross Margin = 85.41% ((Revenue TTM 386.1m - Cost of Revenue TTM 56.4m) / Revenue TTM)
Tobins Q-Ratio = -1.65 (set to none) (Enterprise Value 1.56b / Book Value Of Equity -945.6m)
Interest Expense / Debt = 3.24% (Interest Expense 6.58m / Debt 202.6m)
Taxrate = 21.0% (US default)
NOPAT = -41.9m (EBIT -41.9m, no tax applied on loss)
Current Ratio = 4.30 (Total Current Assets 351.6m / Total Current Liabilities 81.7m)
Debt / Equity = 1.45 (Debt 202.6m / last Quarter total Stockholder Equity 139.5m)
Debt / EBITDA = -6.31 (Net Debt 116.6m / EBITDA -32.1m)
Debt / FCF = -4.42 (Debt 202.6m / FCF TTM -45.8m)
Total Stockholder Equity = 154.2m (last 4 quarters mean)
RoA = -12.08% (Net Income -56.4m, Total Assets 466.8m )
RoE = -36.57% (Net Income TTM -56.4m / Total Stockholder Equity 154.2m)
RoCE = -11.79% (Ebit -41.9m / (Equity 154.2m + L.T.Debt 201.4m))
RoIC = -13.74% (NOPAT -41.9m / Invested Capital 305.3m)
WACC = 7.50% (E(1.60b)/V(1.80b) * Re(8.12%)) + (D(202.6m)/V(1.80b) * Rd(3.24%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 90.91 | Cagr: 3.46%
Discount Rate = 8.12% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -45.8m)
EPS Correlation: -4.48 | EPS CAGR: 41.13% | SUE: 0.81 | # QB: 0
Revenue Correlation: 82.62 | Revenue CAGR: 195.0% | SUE: N/A | # QB: None
Additional Sources for ARDX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle